Financial Performance - The company's operating revenue for Q1 2021 was ¥121,970,257.25, representing a 32.02% increase compared to ¥92,384,827.51 in the same period last year[8] - Net profit attributable to shareholders for Q1 2021 was ¥7,764,389.66, a significant increase of 363.81% from ¥1,674,030.75 in the previous year[8] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥7,755,443.98, up 205.29% from ¥2,540,317.24 year-on-year[8] - The basic earnings per share for Q1 2021 was ¥0.0153, which is a 363.64% increase compared to ¥0.0033 in the same period last year[8] - The weighted average return on equity for the reporting period was 1.13%, an increase of 0.88% from 0.25% in the previous year[8] - Operating revenue increased by CNY 29.585 million, a growth of 32.02%, driven by increased market demand following a decline in sales due to the pandemic last year[18] - Net profit increased by CNY 6.0904 million, a growth of 363.81%, attributed to increased sales revenue and decreased financial expenses[18] - Basic earnings per share increased by 363.81%, reflecting the growth in net profit[18] - The total operating revenue for Q1 2021 was CNY 121,970,257.25, an increase of 32.2% compared to CNY 92,384,827.51 in the same period last year[39] - The net profit for Q1 2021 was CNY 7,764,389.66, compared to CNY 1,674,030.75 in Q1 2020, representing a significant increase of 363.5%[40] - The total comprehensive income for the period was ¥740,407.74, a recovery from a loss of ¥898,960.27 in the same period last year[44] Cash Flow and Liquidity - The net cash flow from operating activities was -¥2,969,949.07, showing an improvement of 84.89% compared to -¥19,651,242.63 in the same period last year[8] - Cash flow from operating activities increased by CNY 16.6813 million, a growth of 84.49%, primarily due to increased cash received from sales and reduced cash payments for purchases[21] - The company's cash and cash equivalents decreased to CNY 19,723,433.09 from CNY 21,210,482.62, a decline of 7.0%[35] - The total cash and cash equivalents at the end of the period increased to ¥166,505,542.40 from ¥95,240,445.37 at the end of the same period last year[47] - The company's investment activities generated a net cash inflow of ¥32,229,612.31, a recovery from a net outflow of -¥894,872.43 in the previous year[46] - The company’s financing activities resulted in a net cash outflow of -¥4,990,618.71, compared to -¥6,522,436.95 in the previous year[47] - The net cash flow from financing activities was -CNY 4,990,618.71, indicating a decrease in cash from financing operations[50] Assets and Liabilities - Total assets at the end of the reporting period were ¥800,963,760.16, a decrease of 0.92% from ¥808,439,808.13 at the end of the previous year[8] - The total assets as of March 31, 2021, amounted to CNY 497,701,703.64, slightly up from CNY 496,746,348.50 at the end of 2020[36] - The total liabilities as of March 31, 2021, were CNY 71,682,860.88, compared to CNY 71,467,913.48 at the end of 2020, indicating a marginal increase[36] - The inventory level decreased to CNY 34,474,494.23 from CNY 41,515,925.54, a reduction of 16.9%[35] - The total equity attributable to the parent company as of March 31, 2021, was CNY 690,770,430.72, compared to CNY 683,006,041.06 at the end of 2020, reflecting a growth of 1.1%[36] Shareholder Information - The company reported a total of 28,039 common shareholders at the end of the reporting period[11] - The top shareholder, Shenzhen Tiger Fund Management Co., Ltd., held 11.27% of the shares, amounting to 57,200,000 shares, which are currently pledged[11] Other Financial Metrics - Accounts receivable increased by CNY 19.589 million, a growth of 60.99%, mainly due to an increase in notes received from sales[18] - Other receivables decreased by CNY 25.1003 million, a decline of 73.73%, mainly due to the recovery of CNY 32.5 million from a debt[18] - Financial expenses decreased by CNY 1.5113 million, a decline of 129.21%, due to a reduction in total bank loans and interest expenses[18] - Income tax expenses increased by CNY 1.1908 million, a growth of 190.72%, due to an increase in total profit[18] - Sales expenses increased by CNY 25.7298 million, a growth of 68.96%, as last year's expenses were lower due to pandemic-related restrictions[18] Audit Status - The company has not undergone an audit for the Q1 2021 report, indicating that the figures are unaudited[51]

Financial Performance - The company's operating revenue for 2020 was CNY 544,728,979.12, an increase of 8.84% compared to CNY 500,504,004.47 in 2019[17] - The net profit attributable to shareholders in 2020 was CNY 19,838,348.25, a significant turnaround from a loss of CNY 122,184,478.40 in 2019, representing a 116.24% increase[17] - The net cash flow from operating activities reached CNY 96,873,550.55, marking a substantial increase of 647.25% from CNY 12,963,921.39 in the previous year[17] - Basic earnings per share for 2020 were CNY 0.0391, compared to a loss of CNY 0.2408 per share in 2019, reflecting a 116.24% improvement[17] - The total assets at the end of 2020 were CNY 808,439,808.13, a decrease of 5.55% from CNY 855,938,235.20 at the end of 2019[18] - The net assets attributable to shareholders increased by 2.99% to CNY 683,006,041.06 at the end of 2020, up from CNY 663,167,692.81 in 2019[18] - The weighted average return on net assets was 2.95% in 2020, a significant recovery from -16.87% in 2019, indicating improved profitability[17] Market and Industry Insights - The Chinese pharmaceutical market is the second largest globally, driven by economic growth, increased public health spending, and an aging population, although growth rates are declining[29] - The COVID-19 pandemic has temporarily boosted the demand for certain traditional Chinese medicine products, enhancing market sales and prices[30] - The average profit margin in the traditional Chinese medicine sector has been declining due to rising raw material costs and increased R&D expenditures[30] - The company has a diverse product portfolio with over 60 varieties, primarily in traditional Chinese medicine, including categories like throat, cold, orthopedic, and rheumatology[26] Operational Developments - The company has not reported any changes in its main business since its listing, indicating stability in its operational focus[16] - The company invested in GMP upgrades and automation of production equipment, which reduced labor costs and improved production efficiency[37] - The marketing strategy focused on optimizing regional management and maintaining price stability, leading to improved sales channels[37] - The production volume increased by 15.71% to ¥131,159,075.35, while inventory decreased by 5.17% to ¥72,798,553.45[46] Risk Management - The company has acknowledged potential risks including industry policy changes and intensified market competition, which may impact future performance[4] - The company is facing challenges from industry competition and regulatory changes, which may impact future growth prospects[29] - The company faces risks related to market concentration on its main products, which could impact revenue if market conditions change[73] - The company is addressing cost control risks due to price declines in the pharmaceutical market and potential increases in raw material costs[75] Corporate Governance and Compliance - The company has established a comprehensive environmental management system, ensuring compliance with the Environmental Protection Law and related regulations, with all pollution control facilities designed and constructed simultaneously with the main project[133] - The company has a complete corporate governance structure, ensuring timely and accurate information disclosure to protect shareholder and creditor rights[125] - The company has committed to avoiding related party transactions that could conflict with its interests, ensuring fair and reasonable pricing for necessary transactions[88] - The company has established a legal commitment to avoid any related party transactions that could harm its interests[90] Shareholder Relations and Dividends - The company plans not to distribute cash dividends or issue bonus shares for the year[5] - The company committed to distributing at least 10% of the annual distributable profit in cash dividends, with a cumulative cash distribution over three consecutive years not less than 30% of the average annual distributable profit achieved during that period[91] - The company will actively adopt cash distribution methods for profit allocation over the next three years, prioritizing cash dividends over stock dividends[91] Environmental Compliance - The company has implemented five environmental protection measures to ensure compliance with national and local pollution discharge standards[127] - The pollution discharge permit for the company is valid from August 18, 2020, to August 17, 2023, confirming that major pollutants are within the discharge standards[136] - The company achieved a 100% disclosure rate for its environmental self-monitoring data from 2019 to 2020[138] Employee Welfare and Management - The company emphasizes employee welfare, providing a good working environment and comprehensive social insurance[126] - The company employs a total of 764 staff, with 231 in production, 230 in sales, and 99 in technical roles[171] - The compensation structure consists of basic salary, position salary, performance salary, allowances, and benefits, closely linked to company performance and individual contributions[172] Financial Reporting and Audit - The company has implemented changes in accounting policies effective from January 1, 2020, including the new revenue recognition standard and lease accounting standard, which will not significantly impact total assets, net assets, or net profit[99][103] - The internal control audit report confirmed that the company maintained effective financial reporting internal controls as of December 31, 2020[200] - The internal control audit report was disclosed on April 20, 2021, and received a standard unqualified opinion[200]

广东嘉应制药股份有限公司 2020 年第三季度报告全文 广东嘉应制药股份有限公司 2020 年第三季度报告 2020-041 2020 年 10 月 1 一、主要会计数据和财务指标 广东嘉应制药股份有限公司 2020 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陈建宁、主管会计工作负责人宋稚牛及会计机构负责人(会计主 管人员)陈晓燕声明：保证季度报告中财务报表的真实、准确、完整。 2 广东嘉应制药股份有限公司 2020 年第三季度报告全文 第二节 公司基本情况 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 836,554,265.14 | 855,938,235.21 | | -2.26% | | 归属于上市公司股东的净资产（元） | 662 ...

Financial Performance - The company's operating revenue for the first half of 2020 was ¥208,250,220.53, a decrease of 2.96% compared to ¥214,593,888.62 in the same period last year[17]. - The net profit attributable to shareholders was a loss of ¥2,893,941.22, representing a decline of 120.82% from a profit of ¥13,899,583.73 in the previous year[17]. - The basic earnings per share were reported at -¥0.0057, a decrease of 120.80% compared to ¥0.0274 in the same period last year[17]. - The net profit for the period was a loss of CNY 2.89 million[30]. - The company reported a significant increase in net cash flow from operating activities, rising by 151.80% to CNY 17.11 million[32]. - The total comprehensive income for the first half of 2020 was a loss of CNY 2.89 million, contrasting sharply with a gain of CNY 13.90 million in the same period of 2019[130]. - The company reported a net loss of CNY 255,502,469.18 for the period, compared to a loss of CNY 252,569,822.31 in the previous period[125]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly to ¥17,105,615.86, compared to a negative cash flow of ¥33,022,051.56 in the same period last year, marking a 151.80% increase[17]. - Cash flow from investment activities increased by 96.06 million yuan, a growth of 106.76%, mainly due to reduced cash payments for investments[33]. - The company received ¥55,000,000.00 from borrowings in the first half of 2020, an increase from ¥30,000,000.00 in the same period of 2019[141]. - The net cash flow from financing activities was -¥22,346,460.08, a decrease from a net inflow of ¥64,047,791.04 in the previous year[138]. - The ending balance of cash and cash equivalents was ¥123,151,134.41, compared to ¥55,995,138.63 at the end of the previous year[138]. Assets and Liabilities - The total assets at the end of the reporting period were ¥825,012,740.65, down 3.61% from ¥855,938,235.20 at the end of the previous year[17]. - The total liabilities decreased by 8.71% compared to the previous year, reflecting a reduction in accounts payable and other payables[39]. - Short-term borrowings amounted to 75 million yuan, representing 9.09% of total assets, a decrease from 84 million yuan in the previous year[39]. - The total equity attributable to shareholders decreased from CNY 663,167,692.82 to CNY 660,273,751.59, a decline of about 0.4%[121]. Operational Efficiency and Costs - Operating costs increased by 19.53% to CNY 61.18 million, primarily due to rising raw material and labor costs[32]. - Sales expenses rose by 2.28% to CNY 113.03 million, while management expenses decreased by 13.95% to CNY 27.60 million[32]. - Financial expenses surged by 89.95% to CNY 1.81 million, mainly due to increased interest payments on short-term bank loans[32]. - The gross profit margin for the pharmaceutical sector was 70.39%, down 5.50% year-on-year, with operating costs increasing by 19.53%[36]. Strategic Initiatives and Future Outlook - The company plans not to distribute cash dividends or issue bonus shares for this period[6]. - The company is focusing on the secondary development of its main products, which include Shuangliao Houfeng San and Jiekou Qiqi Pian, to mitigate risks associated with product concentration[53]. - The company plans to enhance operational efficiency and reduce costs by optimizing procurement and production processes[56]. - The company provided a positive outlook for the second half of 2020, projecting a revenue growth of 10% to 15% based on current market trends[64]. - The company plans to invest 100 million RMB in research and development over the next three years to foster innovation and improve product efficacy[64]. Environmental and Compliance - The company is classified as a key pollutant discharge unit by environmental protection authorities[88]. - The company has reported no significant environmental violations or exceedances of discharge standards[88]. - The pollution discharge permit for the company is valid until December 31, 2021, with all major pollutants meeting discharge standards[92]. - The company has established an environmental management system and has fully complied with environmental impact assessment requirements for its projects[92]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 33,804, with no changes in the controlling shareholder or actual controller[100][102]. - The top ten shareholders included Shenzhen Tiger Fund Management Co., Ltd. with an 11.27% stake and Chen Yonghong with a 10.94% stake[100]. - The company has maintained a total of 507,509,848 shares, with no changes in the number of shares during the reporting period[98]. Corporate Governance - The company has made commitments to avoid related party transactions and ensure fair pricing in any necessary transactions[62]. - The commitments include avoiding substantial competition with its subsidiaries and ensuring the protection of minority shareholders' interests[63]. - Management emphasized the importance of compliance with legal regulations and maintaining fair trading practices to protect shareholder interests[65].

Financial Performance - The company's operating revenue for 2019 was ¥500,504,004.47, a decrease of 6.79% compared to ¥536,983,626.24 in 2018[17] - The net profit attributable to shareholders was -¥122,184,478.40, representing a decline of 440.55% from a profit of ¥35,878,607.29 in the previous year[17] - The net cash flow from operating activities decreased by 79.13%, amounting to ¥12,963,921.39 compared to ¥62,102,737.57 in 2018[17] - The basic earnings per share were -¥0.2408, a drop of 441.08% from ¥0.0706 in 2018[17] - Total assets at the end of 2019 were ¥855,938,235.20, down 3.78% from ¥889,559,036.66 at the end of 2018[18] - The net assets attributable to shareholders decreased by 15.56%, totaling ¥663,167,692.82 compared to ¥785,352,171.22 in 2018[18] - The weighted average return on net assets was -16.85%, a decrease of 21.52% from 4.67% in 2018[18] - The company achieved a total operating revenue of RMB 500.50 million in 2019, representing a year-on-year decrease of 6.79%[42] - The net profit for the year was RMB -12.22 million, indicating a loss[42] - The company's total assets amounted to RMB 855.94 million, with shareholders' equity at RMB 663.17 million as of December 31, 2019[42] Cash Flow and Investments - The net cash flow from operating activities improved significantly from a negative CNY 28.85 million in Q1 2019 to a positive CNY 47.50 million in Q4 2019[22] - The net cash flow from investing activities was negative CNY 105,117,160.06, a significant decline of 1,448.82% compared to negative CNY 6,786,922.00 in 2018[60] - The net cash flow from financing activities increased by 545.58% to CNY 99,514,186.23 from negative CNY 22,333,643.60 in 2018[60] - Long-term equity investments increased by RMB 34.36 million, a growth of 124.79%, primarily due to additional investments in Kangci Medical[37] Market and Product Strategy - The company has a diverse product portfolio with over 60 varieties, focusing on traditional Chinese medicine in categories such as throat, cold, orthopedic, and rheumatology[27] - The company aims to deepen its focus on traditional Chinese medicine, particularly in specialized disease areas, and is committed to innovation[36] - The pharmaceutical industry is undergoing significant changes due to government reforms, which may impact sales and profit margins for many companies[33] - The demand for traditional Chinese medicine is increasing, supported by government policies and growing public awareness[34] - The company is positioned to leverage its unique products and brand influence in the traditional Chinese medicine market[36] - The COVID-19 pandemic highlighted the effectiveness of traditional Chinese medicine in treating viral infections, providing a growth opportunity for the industry[35] - The company plans to enhance its R&D capabilities, focusing on secondary development of existing products and establishing partnerships with educational institutions[42] - The company is actively developing new products and expanding its market presence, with sales of new products significantly increasing and becoming new profit growth points[79] Risk Factors - The company faces risks related to industry policy changes, concentrated main products, intensified market competition, and new drug development[4] - The company has not made any commitments regarding future development statements, highlighting the importance of investor risk awareness[4] - The company faces significant market risks due to a lack of product diversity and weak core competitiveness, which has resulted in a challenging operating environment[77] - The company has faced challenges with drug price controls and rising costs of raw materials, which have impacted profitability and operational efficiency[80] Governance and Compliance - The company has maintained a complete governance structure, holding 1 annual general meeting and 1 extraordinary general meeting, along with 8 board meetings and 7 supervisory meetings during the reporting period[136] - The independent directors have acknowledged the audit report with reserved opinions and emphasized the need for the board to address related issues effectively[112] - The supervisory board supports the board's actions regarding the audit report and will monitor the progress of related measures[113] - The company is committed to compliance with regulatory requirements and has established governance structures to oversee its operations[170] - The company’s independent directors' suggestions aim to enhance internal supervision and protect investors' rights[154] Shareholder and Dividend Policy - The company plans not to distribute cash dividends or issue bonus shares[5] - The company has revised its cash dividend policy to ensure clear decision-making processes and protect shareholder interests[86] - The company has not distributed profits or increased capital reserves in the last three years, indicating a focus on reinvestment rather than immediate shareholder returns[89] - The company did not propose any cash dividend distribution plan for the reporting period, despite having positive profits available for distribution to ordinary shareholders[90] - The actual controller and shareholders have fulfilled their commitments during the reporting period, including avoiding and regulating related party transactions[92] Employee and Management Structure - The company employed a total of 827 staff members, including 410 in the parent company and 417 in major subsidiaries[196] - The professional composition of employees includes 280 production personnel, 263 sales personnel, 85 technical personnel, 16 financial personnel, 68 administrative personnel, and 115 logistics personnel[196] - The remuneration policy is based on a five-part structure: basic salary, position salary, performance salary, allowances/subsidies, and benefits[198] - The company emphasizes employee training, focusing on enhancing overall capabilities and specific job skills for middle and senior management[199] - The management team includes experienced professionals from the pharmaceutical industry, with key positions held by individuals with significant prior experience[182] Environmental Compliance - The company has implemented five environmental protection initiatives, including boiler flue gas waste heat utilization and wastewater treatment upgrades, ensuring compliance with national and local pollution discharge standards[138] - The company has improved and optimized its wastewater treatment facilities, reducing operational costs while ensuring compliance with environmental standards[146] - The pollution discharge permit for the company is valid from February 15, 2017, to December 31, 2021, and all major pollutants are discharged within the standards[149] - The company is classified as a key pollutant discharge unit by the environmental protection department, with a total of 1 wastewater discharge outlet and 1 boiler flue gas discharge outlet[146]

广东嘉应制药股份有限公司 2020 年第一季度报告全文 广东嘉应制药股份有限公司 2020 年第一季度报告 2020-014 2020 年 04 月 1 广东嘉应制药股份有限公司 2020 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人陈建宁、主管会计工作负责人宋稚牛及会计机构负责人(会计主 管人员)陈晓燕声明：保证季度报告中财务报表的真实、准确、完整。 2 广东嘉应制药股份有限公司 2020 年第一季度报告全文 第二节 公司基本情况 √ 适用 □ 不适用 单位：元 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 92,384,827.51 | 87,770,964.01 | 5.26% | | 归属于上市公司股东的净利润（元） | 1,674,030 ...

Financial Performance - Operating revenue for the reporting period was ¥123,518,936.91, reflecting a year-on-year growth of 1.50%[7] - Net profit attributable to shareholders was ¥6,819,903.68, representing a significant increase of 21.23% year-on-year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥6,516,469.56, up 15.07% compared to the same period last year[7] - Basic earnings per share for the reporting period was ¥0.0134, an increase of 20.72% year-on-year[7] - The company reported a significant increase in revenue for Q3 2019, with total revenue reaching RMB 1.2 billion, representing a year-on-year growth of 15%[23] - The company's net profit for Q3 2019 was not explicitly stated, but the total equity attributable to shareholders increased to CNY 806,071,658.63 from CNY 785,352,171.22 year-over-year, reflecting a growth of approximately 2.3%[36] - The net profit for Q3 2019 reached CNY 6,819,903.68, up from CNY 5,625,786.33, representing a growth of 21.2% year-over-year[49] - The total profit for Q3 2019 was CNY 8,697,942.60, compared to CNY 7,518,614.74 in the same quarter last year, reflecting a growth of 15.7%[47] - The total profit for Q3 2019 was CNY 25,456,700.14, compared to CNY 21,482,589.65 in the previous year, marking an increase of 18.5%[52] Cash Flow and Investments - Cash flow from operating activities showed a net outflow of ¥1,512,636.44, a decline of 4.58% compared to the previous period[7] - Cash received from operating activities increased by 139.34% year-on-year, totaling 16.85 million yuan, mainly due to an increase in external receivables[18] - Net cash flow from operating activities decreased by 325.92% year-on-year, amounting to a reduction of 49.82 million yuan, primarily due to increased prepayments for raw material purchases and higher sales expenses[18] - Cash flow from investing activities decreased by 2,350.57% year-on-year, amounting to a reduction of 91.26 million yuan, primarily due to increased cash outflows for finance lease assets and investments in Guangdong Kangci Medical Management Co., Ltd.[19] - Cash flow from financing activities increased by 398.63% year-on-year, totaling an increase of 84.06 million yuan, primarily due to an increase in bank borrowings and a decrease in repayments[19] - The cash flow from operating activities showed a net outflow of CNY -34,534,688.00, contrasting with a net inflow of CNY 15,285,976.26 in the previous year[60] - The net cash flow from financing activities was ¥18,831,620.01, a recovery from a negative cash flow of -¥21,088,255.27 in the same period last year[65] Assets and Liabilities - Total assets at the end of the reporting period reached ¥969,809,027.10, an increase of 9.02% compared to the previous year[7] - The company’s total liabilities increased by 342.11% due to a rise in short-term borrowings amounting to ¥65,000,000[15] - The company's current assets totaled CNY 409,635,924.29, slightly up from CNY 404,477,872.06 at the end of 2018[34] - Current liabilities totaled CNY 128,719,480.89, significantly higher than CNY 69,164,004.03 in the previous year, marking an increase of about 86.3%[35] - The total liabilities of the company increased, reflecting a growing leverage position, although specific figures were not detailed in the provided content[34] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 36,564[11] - The company has committed to distributing at least 10% of its distributable profits in cash annually over the next three years[26] - The company plans to maintain a cash dividend distribution policy, with a minimum of 30% of the average annual distributable profits over three years to be distributed[26] Strategic Initiatives - The company decided to terminate the major asset restructuring plan due to high financing difficulties and complex procedures, with a commitment not to plan any major asset restructuring within six months after the announcement[20] - The company plans to continue promoting the feasibility of various restructuring schemes while strictly fulfilling information disclosure obligations[20] - The company is investing in R&D, with a budget allocation of RMB 150 million for the development of new technologies and products in the upcoming fiscal year[23] - Market expansion plans include entering two new provinces, which are projected to increase market share by 5%[24] - The company is considering strategic acquisitions to enhance its competitive position, with potential targets identified in the pharmaceutical sector[23] - The company plans to continue focusing on market expansion and new product development as part of its strategic initiatives[56] Operational Efficiency - Operating costs decreased by 26.26% year-on-year, amounting to a reduction of 26.35 million yuan, primarily due to adjustments in product sales structure and an increase in overall gross profit margin by 8.07%[17] - The gross margin for Q3 2019 was reported at 45%, a slight increase from 43% in the previous quarter, indicating improved operational efficiency[23] - The company aims to reduce operational costs by 8% through process optimization initiatives in the next quarter[24] - The company's sales expenses for Q3 2019 were CNY 7,435,999.69, a substantial increase from CNY 2,013,605.86, indicating a rise of 269.5% year-over-year[47] - The financial expenses for the quarter were CNY 1,153,522.75, slightly down from CNY 1,227,284.38, indicating improved cost management[56]

广东嘉应制药股份有限公司 2019 年半年度报告全文 广东嘉应制药股份有限公司 2019 年半年度报告 2019-053 2019 年 08 月 1 广东嘉应制药股份有限公司 2019 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 公司负责人陈建宁、主管会计工作负责人宋稚牛及会计机构负责人(会计主 管人员)陈晓燕声明：保证本半年度报告中财务报告的真实、准确、完整。 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本报告的董事会会议。 报告期内可能存在行业政策变化、主导产品较为集中、市场竞争加剧、新 药开发等风险，详见本报告第四节"经营情况讨论与分析" 的"十、公司面临 的风险和应对措施" 中对公司可能面临风险的相关描述，敬请广大投资者注意 投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 目录 | | - ...

广东嘉应制药股份有限公司 2019 年第一季度报告 2019-031 2019 年 04 月 1 广东嘉应制药股份有限公司 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 广东嘉应制药股份有限公司 2019 年第一季度报告全文 公司负责人陈建宁、主管会计工作负责人宋稚牛及会计机构负责人(会计主 管人员)陈晓燕声明：保证季度报告中财务报表的真实、准确、完整。 2 广东嘉应制药股份有限公司 2019 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 87,770,964.01 | 93,430,702.81 | -6.06% | | 归属于上市公司股东的净利润（元） | 8,477,275.40 | 8 ...

Financial Performance - The company's operating revenue for 2018 was CNY 536,983,626.24, representing a 14.72% increase compared to CNY 468,080,735.66 in 2017[17]. - The net profit attributable to shareholders for 2018 was CNY 35,878,607.29, a significant turnaround from a loss of CNY 214,761,693.31 in 2017, marking a 116.71% increase[17]. - The net cash flow from operating activities reached CNY 62,102,737.57, up 102.74% from CNY 30,631,917.68 in the previous year[17]. - Basic earnings per share improved to CNY 0.0706 in 2018, compared to a loss of CNY 0.4232 in 2017, reflecting a 116.68% increase[17]. - The total output value for the year reached CNY 648 million, representing a year-on-year increase of 11.35%[40]. - The company achieved an operating income of CNY 537 million, up 14.72% compared to the previous year[40]. - Net profit for the year was CNY 35.88 million, reflecting a significant year-on-year growth of 116.71%[40]. - The total cash and cash equivalents increased by 282.10% to ¥32.98 million in 2018, compared to an increase of ¥8.63 million in 2017[63]. Assets and Liabilities - The total assets at the end of 2018 were CNY 889,559,036.66, a 1.48% increase from CNY 876,610,240.21 at the end of 2017[18]. - The net assets attributable to shareholders increased by 4.74% to CNY 785,352,171.22 at the end of 2018, up from CNY 749,810,780.63 in 2017[18]. - Accounts receivable reached 151,887,724.26, accounting for 17.07% of total assets, a slight increase of 0.14% from the previous year[66]. - Inventory increased to 71,707,150.09, making up 8.06% of total assets, up by 0.84% year-on-year[66]. - Fixed assets decreased to 250,981,884.0, representing 28.21% of total assets, down by 2.02% from 2017[67]. - Short-term borrowings were reported at 19,000,000.00, which is 2.14% of total assets, a decrease of 2.42% compared to the previous year[67]. Market and Competition - The pharmaceutical industry in China grew by 10.4% in the first eight months of 2018, indicating a robust demand for healthcare products despite a slight slowdown in growth rates[34]. - The company has a diverse product portfolio with over 60 varieties, primarily in traditional Chinese medicine, which has gained significant market share and brand recognition[27]. - The company’s main products include unique and patented traditional Chinese medicines, which are well-received in the market, enhancing its competitive edge[27]. - The competitive landscape in the traditional Chinese medicine industry is intensifying, with over 1,000 companies, leading to lower average profit margins[87]. Strategic Initiatives - The company is focused on expanding its market presence and enhancing its product offerings in response to the growing healthcare needs of the population[34]. - The company completed the first phase of investment in Kangci Medical, which plans to establish three specialized hospitals for neurodegenerative diseases[45]. - Plans to expand the network of specialized hospitals for neurodegenerative diseases across major cities in China within three years, leveraging early diagnostic tools for Alzheimer's disease[80]. - The company aims to optimize key products and develop high-end consumer-targeted products to enhance sales profit and expand market presence, with significant revenue growth expected from various traditional Chinese medicine products[76]. Risks and Challenges - The company faces risks related to industry policy changes, concentrated main products, intensified market competition, and new drug development[4]. - Regulatory changes in the pharmaceutical industry pose risks, prompting the company to strengthen internal management and operational efficiency to adapt to new compliance requirements[84]. - The company faced risks from price declines and cost control, with a focus on optimizing procurement and production processes to mitigate rising raw material costs[86]. - The company is transitioning to specialized hospitals for dementia care, which requires significant upfront investment and may not yield short-term profits[90]. Governance and Compliance - The company is committed to protecting the interests of minority shareholders and ensuring compliance with relevant laws and regulations[104]. - The company guarantees not to engage in any business that competes with its main business during the reporting period[106]. - The company has committed to avoiding related party transactions and ensuring fair pricing in unavoidable transactions[103]. - The company emphasizes compliance with legal and regulatory requirements in all transactions to maintain transparency and fairness[112]. Management and Leadership - The company has seen a significant turnover in its board, with a total of 10 members leaving as of August 13, 2018, which may impact future strategic decisions[183]. - The company appointed Chen Jianning as chairman in August 2018, with a background in finance and extensive experience in investment management[184]. - The management team emphasizes the importance of compliance and governance in driving the company's growth strategy[191]. - The company has a strong management team with expertise in finance, law, and pharmaceutical operations, ensuring effective oversight and strategic direction[192]. Shareholder Returns - The company plans not to distribute cash dividends or issue bonus shares for the year[5]. - The company did not distribute cash dividends for the fiscal year 2018, with a total cash dividend amount of 0.00, representing 0.00% of the net profit attributable to ordinary shareholders[100]. - The company plans to distribute cash dividends amounting to at least 10% of the distributable profit achieved in the current year, with a cumulative distribution of no less than 30% of the average annual distributable profit over three consecutive years[115]. - The cumulative cash dividends from 2016 to 2018 amounted to approximately ¥20.3 million, representing -49.20% of the average distributable profit during that period[95].